BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Akebia Therapeutics, Inc. Completes $22M Series B Financing


4/26/2011 9:19:09 AM

CINCINNATI, OH--(Marketwire - April 26, 2011) - Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has closed a Series B Preferred stock financing totaling $22 million. The oversubscribed Series B round was led by the Company's existing investors, Novartis Venture Fund and Venture Investors, LLC. Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital and new investors, including AgeChem Venture Fund, participated in the round.

The $22 million Series B round includes a $14 million first closing. In addition, the Company has the right to access another $8 million through the end of 2011.

"This is an important financing event for Akebia because it enables us to complete two phase 2b studies for our anemia drug, AKB-6548 and will position the program for pivotal studies," said Joseph Gardner, Ph.D., President and Chief Executive Officer of Akebia. "This financing round also enables us to advance AKB-9778, our novel Tie-2 activator for diabetic macular edema and vascular leak, into the clinic."

Akebia's lead compound, AKB-6548, which is in phase 2 is a potentially best-in-class hypoxia inducible factor -- prolyl hydroxylase (HIF-PH) inhibitor for the treatment of anemia. AKB-6548 offers many potential advantages, including an improved safety profile, oral dosing and lower cost of goods, over traditional erythropoiesis stimulating agents (ESAs) currently used to treat anemia. Akebia also has a platform of novel Tie-2 activators / HPTP beta inhibitors for the treatment of diabetic macular edema and vascular leak.

"The anemia market is very large and there is a tremendous need for new therapies that are safer and easier to use than the current injectable ESAs," said Louis Lacasse, Managing Partner of AgeChem. "We are very excited about joining such an elite group of investors to support the development of AKB-6548, which we believe could be a blockbuster drug for the treatment of anemia."

About Akebia Therapeutics
Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia's lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia, is in phase 2 clinical trials. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimulate endogenous EPO production. Additionally, Akebia has a novel Tie-2 activator (HPTP beta inhibitor), AKB-9778, for the treatment of diabetic macular edema and vascular leak syndrome which is scheduled to commence phase 1 clinical trials in the second half of 2011.

Website: www.akebia.com.


CONTACT:

Joseph Gardner
Chief Executive Officer
Akebia Therapeutics, Inc.
513-985-1920
Email Contact

Michelle Linn
Linnden Communications
(o) 508-362-3087
(m) 774-696-3803
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES